Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non‐Small Cell Lung Cancer

Background. Reports serve as a bridge between laboratories and clinicians, help synthesize an overwhelming amount of raw data into evidence‐based medicine, and play a significant role in designing clinical treatments. In an effort to guarantee high‐quality epidermal growth factor receptor (EGFR) gene mutation testing and reporting performance, the National Center for Clinical Laboratories launched a proficiency testing (PT) scheme reflecting clinical practices in China since 2014. This study focuses on the quality assessment of gene mutation reports.